Related Experiment Video
Updated: Jul 16, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Giant prostate carcinoma treated effectively with endocrine therapy: case report]
Naruyasu Masue1, Yoshikazu Hasegawa
1The Department of Urology, Matsunami General Hospital.
Hinyokika Kiyo. Acta Urologica Japonica
|March 14, 2007
Summary
A giant prostate tumor in an 87-year-old man significantly shrank with combined androgen blockade therapy. This treatment effectively managed advanced prostate cancer, preventing hormone resistance for at least one year.
Area of Science:
- Urology
- Oncology
Background:
- Advanced prostate cancer presents significant clinical challenges.
- Giant prostate tumors require effective therapeutic strategies.
Observation:
- An 87-year-old male presented with abdominal distention and urinary retention due to a giant prostate tumor.
- Imaging (CT and MRI) confirmed the large tumor size.
- Histological diagnosis revealed moderately differentiated adenocarcinoma of the prostate, clinical stage T4N0M0 (Stage IV).
Findings:
- Combined androgen blockade therapy led to a marked reduction in tumor size within four months.
- Serum prostate-specific antigen (PSA) levels normalized post-treatment.
- The patient did not develop hormone-refractory prostate cancer one year after treatment initiation.
Implications:
- Combined androgen blockade is an effective treatment for giant, advanced prostate adenocarcinoma.
- Early and appropriate therapy can prevent the progression to hormone-refractory disease.
- This case highlights successful management of a rare presentation of prostate cancer.
